articleTop 1% cited
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
The Lancet Oncology · 2005 · Vol. 6(5) · pp. 271–278
Luisa L. Villa✉(Ludwig Cancer Research)Ronaldo Lúcio Rangel Costa(Instituto Brasileiro de Controle do Câncer)Carlos Alberto Petta(Universidade Estadual de Campinas (UNICAMP))Rosíres Pereira de Andrade(Centro de Reprodução Humana Prof. Franco Junior)Kevin A. Ault(University of Iowa)Anna R. Giuliano(University of Arizona Cancer Center)Cosette M. Wheeler(University of New Mexico)Laura A. Koutsky(University of Washington)Christian Malm(Institute for Molecular Medicine Finland)Matti Lehtinen(Institute for Molecular Medicine Finland)Finn Egil Skjeldestad(SINTEF)Sven-Eric Olsson(Karolinska Institutet)Margareta SteinwallDarron R. Brown(Indiana University School of Medicine)Robert J. Kurman(Johns Hopkins University)Brigitte M. Ronnett(Johns Hopkins Medicine)Mark H. Stoler(University of Virginia)Alex Ferenczy(Jewish General Hospital)Diane M. Harper(Dartmouth College)Gretchen Tamms(United States Military Academy)Jimmy Yu(United States Military Academy)Lisa Lupinacci(United States Military Academy)Radha Railkar(United States Military Academy)Frank J. Taddeo(United States Military Academy)Kathrin U. Jansen(United States Military Academy)Mark T. Esser(United States Military Academy)Heather L. Sings(United States Military Academy)Alfred J. Saah(United States Military Academy)Eliav Barr(United States Military Academy)
Cervical Cancer and HPV ResearchHepatitis B Virus StudiesImmunotherapy and Immune ResponsesPlaceboMedicineDouble blindVirus-like particleHuman papillomavirusInternal medicineVirologyRecombinant DNAAlternative medicinePathology
MeSH terms
AdolescentAdultAntibodies, ViralUterine Cervical DysplasiaUterine Cervical NeoplasmsDouble-Blind MethodFemaleHumansOncogene Proteins, ViralPlacebosTumor Virus InfectionsViral VaccinesPapillomaviridaePapillomavirus InfectionsCapsid Proteins
Citations
1,577
FWCI
132.48
field-weighted impact
References
31
Percentile
100%
vs. same field & year
Citations per year
Cited by
Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World
Journal of Clinical Oncology · 2006 · 3,448 citations
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only
Vaccine · 2006 · 496 citations
The global health burden of infection‐associated cancers in the year 2002
International Journal of Cancer · 2006 · 2,920 citations
Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update
International Journal of Cancer · 2007 · 1,683 citations
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
The Journal of Infectious Diseases · 2009 · 627 citations
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine
Vaccine · 2007 · 455 citations
Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease
Vaccine · 2006 · 539 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
References
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles
Virology · 1991 · 503 citations
Classification of papillomaviruses
Virology · 2004 · 3,188 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.